Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	544.87M +416.5%
Revenue (ttm)	361.51M +13.8%
Net Income	102.18M
EPS	0.62
Shares Out	164.61M
PE Ratio	5.36
Forward PE	2.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,334,361
Open	3.365
Previous Close	3.400
Day's Range	3.305 - 3.470
52-Week Range	0.562 - 5.780
Beta	0.24
Analysts	Buy
Price Target	6.10 (+84.29%)
Earnings Date	May 7, 2026

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://ironwoodpharma.com

Financial Performance

In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.

Analyst Summary

According to 4 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price target is $6.1, which is an increase of 84.29% from the latest price.

Price Target

$6.1

(84.29% upside)

Analyst Consensus: Buy